HC	OOLEY DICKINSON DSPITAL achusetts general hospital affiliate		(Patient Stic	ker)
	PHYSICIAN ORDER SET : RITUXIMAB RHEUMATOLOGY			
	CDH 208-237 – Approved - Pa	age 1 of 5		
^{>} atient:		DOB:	Gender:	
Patient Pho	ne #:	Height:	Weight:	
Diagnosis:		ICD-10 Code:		
Freatment S	Start Date:			
^{>} rovider Fa	cility Name:	Provider Facility Addre	ss:	
Ordering Pr	ovider:	Date:		
Signatura				
	Complete, Sign, and fax this doxument	to: CDH Central Schedul	-	
	clude H&P/current medications list/allergies, a	to: CDH Central Schedul	-	
	clude H&P/current medications list/allergies, a	to: CDH Central Schedul and ensure that med author	izations have been c	btained**
ayor Requ	clude H&P/current medications list/allergies, a	to: CDH Central Schedul and ensure that med author	izations have been c	
Payor Requ	irements imab Medical Necessity Documentation ne, Until discontinued, Starting S For Until specified patient have moderate to severe active RA?	to: CDH Central Schedul and ensure that med author	izations have been c	bbtained** Duration
ayor Requ Ritux Routir Does re-Medicat	irements imab Medical Necessity Documentation ne, Until discontinued, Starting S For Until specified patient have moderate to severe active RA?	to: CDH Central Schedul and ensure that med author	I Defer Until	bbtained** Duration
ayor Requ Ritux Routir Does re-Medicat aceta 325 m	irements imab Medical Necessity Documentation ne, Until discontinued, Starting S For Until specified patient have moderate to severe active RA? ions	to: CDH Central Schedul and ensure that med author Interva Once	I Defer Until	Duration 1 treatment Duration
ayor Requ Ritux Routir Does re-Medicat aceta 325 m Admir	irements imab Medical Necessity Documentation ne, Until discontinued, Starting S For Until specified patient have moderate to severe active RA? ions minophen (TYLENOL) tablet 325 mg	to: CDH Central Schedul and ensure that med author Interva Once	I Defer Until	Duration 1 treatment Duration
ayor Requ Ritux Routir Does re-Medicat 325 m Admir Iorata 10 mg	irements imab Medical Necessity Documentation ne, Until discontinued, Starting S For Until specified patient have moderate to severe active RA? ions minophen (TYLENOL) tablet 325 mg ng, Oral, Once, Starting S, For 1 Doses nister at least 30 mins prior to treatment. adine (CLARITIN) tablet 10 mg n, Starting S	to: CDH Central Schedul and ensure that med author Interva Once Interva 1 time week	I Defer Until	Duration 1 treatment Duration 4 treatments
Payor Requ Ritux Routir Does Pre-Medicat aceta 325 m Admir I lorata 10 mg diphe	irements imab Medical Necessity Documentation ne, Until discontinued, Starting S For Until specified patient have moderate to severe active RA? ions minophen (TYLENOL) tablet 325 mg ng, Oral, Once, Starting S, For 1 Doses nister at least 30 mins prior to treatment. adine (CLARITIN) tablet 10 mg n, Starting S enhydrAMINE (BENADRYL) tablet 25 mg	to: CDH Central Schedul and ensure that med author Interva Once Interva 1 time week	a	Duration 1 treatment Duration 4 treatments
ayor Requ Ritux Routir Does re-Medicat aceta 325 m Admir lorata 10 mg Q diphe 25 mg	irements imab Medical Necessity Documentation ne, Until discontinued, Starting S For Until specified patient have moderate to severe active RA? ions minophen (TYLENOL) tablet 325 mg ng, Oral, Once, Starting S, For 1 Doses nister at least 30 mins prior to treatment. adine (CLARITIN) tablet 10 mg n, Starting S enhydrAMINE (BENADRYL) tablet 25 mg n, Oral, Once, Starting S, For 1 Doses	to: CDH Central Schedul and ensure that med author Interva Once Interva 1 time week 1 time week	a	Duration 1 treatment Duration 4 treatments 4 treatments
Payor Requ Ritux Routir Does Pre-Medicat aceta 325 m Admir 10 mg 25 mg Admir	irements imab Medical Necessity Documentation ne, Until discontinued, Starting S For Until specified patient have moderate to severe active RA? ions minophen (TYLENOL) tablet 325 mg ng, Oral, Once, Starting S, For 1 Doses nister at least 30 mins prior to treatment. adine (CLARITIN) tablet 10 mg n, Starting S enhydrAMINE (BENADRYL) tablet 25 mg	to: CDH Central Schedul and ensure that med author Interva Once Interva 1 time week 1 time week 1 time week	a	Duration 1 treatment Duration 4 treatments 4 treatments
Payor Requ Ritux Routir Does Pre-Medicat aceta 325 m Admir Io ng Comparison Comp	irements imab Medical Necessity Documentation ne, Until discontinued, Starting S For Until specified patient have moderate to severe active RA? ions minophen (TYLENOL) tablet 325 mg ng, Oral, Once, Starting S, For 1 Doses nister at least 30 mins prior to treatment. adine (CLARITIN) tablet 10 mg n, Starting S enhydrAMINE (BENADRYL) tablet 25 mg n, Oral, Once, Starting S, For 1 Doses nister at least 30 mins prior to treatment.	to: CDH Central Schedul and ensure that med author Interva Once Interva 1 time week 1 time week 1 time week 1 time	a	Duration 1 treatment Duration 4 treatments 4 treatments 4 treatments

COOLEY DICKINSON HOSPITAL massachusetts general hospital affiliate			(Patient Stic	ker)
PHYSICIAN ORDER SET :				
RITUXIMAB RHEUMATOLOGY VASCULITIS				
CDH 208-237 – Approved - Page 2 of 5				
Pre-Medications (continued)				
20 mg, Intravenous, Once, Starting S, For 1 Doses Administer at least 30 mins prior to treatment.	Inter	rval	Defer Until	Duration
 hydrocortisone sodium succinate (PF) (Solu-CORTEF) injection 50 mg 50 mg, Intravenous, Once, Starting S, For 1 Doses Administer at least 30 mins prior to treatment. 	1 tin wee			4 treatments
ondansetron (ZOFRAN) tablet 4 mg	1 tin	ne a		4 treatments
4 mg, Oral, Once, Starting S, For 1 Doses HOLD IF: Giving IV. Administer at least 30 mins prior to treatment.	wee	k		
ondansetron (ZOFRAN) IV 8 mg	1 tin wee			4 treatments
8 mg, Intravenous, Once, Starting S, For 1 Doses HOLD IF: Giving PO. Administer at least 30 mins prior to treatment.				
 dexamethasone (DECADRON) 4 mg in sodium chloride 0.9% 50 mL IVPB 4 mg, Intravenous, Once, Starting S, For 1 Doses Administer at least 30 mins prior to treatment. 	1 tin wee			4 treatments
re-Hydrations	_			
	Inter		Defer Until	Duration
 D5-NS infusion 100 mL/hr, Intravenous, Continuous, Starting S 	1 tin wee			4 treatments
□ sodium chloride 0.9% infusion	1 tin wee			4 treatments
150 mL/hr, Intravenous, Continuous, Starting S				
ledications				
	Inter		Defer Until	Duration
□ riTUXimab (RITUXAN) IV 375 mg/m2	1 tin wee			4 treatments

375 mg/m2, Intravenous, for 6 Hours, Once, Starting S, For 1 Doses

Instructions: Administer both the first and second infusion at an initial rate of 50 mg/hour for the first hour. If hypersensitivity or infusion-related events do not occur, escalate the infusion rate in 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. If hypersensitivity or an infusion-related event develops, stop the infusion. The infusion can continue at one-half the previous rate upon improvement of patient symptoms. Subsequent rituximab infusion can be administered at an initial rate of 100 mg/hour for the first 30 minutes and then increased by 100 mg/hour increments at 30-minute intervals, to a maximum of 400 mg/hour as tolerated. Vital signs: q15 minutes during first hour of rituximab, then q 30 minutes and prior to rate changes until completion of infusion. Temporarily discontinue for T>101.3, mucosal edema, >30mm Hg decrease in SBP. Resume rate @50% when symptoms improve.

Labs

	Interval	Defer Until	Duration
CBC and differential	1 time a		4 treatments
	week		
Routine, Once, Starting S For 1 Occurrences, If deemed necessary based upon the results of the automated differential, a manual			
differential may be performed			

Comprehensive metabolic panel 1 time a week

4 treatments

Routine, Once, Starting S For 1 Occurrences, consists of the following tests: Na, K, CI, CO2, BUN, Glucose, Creatinine, Calcium, Albumin, Alkaline Phosphatase, Total Bilirubin, Total Protein, ALT, and AST

\sim	COOLEY DICKINSON
	HOSPITAL
V	MASSACHUSETTS GENERAL HOSPITAL AFFILIATE

(Patient Sticker)

PHYSICIAN ORDER SET :

_

RITUXIMAB RHEUMATOLOGY VASCULITIS

Approved -

CDH 208-237

Page 3 of 5

Labs (continued)

	Interval	Defer Until	Duration
□ C-reactive protein, high sensitivity	1 time a week		4 treatments
Routine, Once, Starting S For 1 Occurrences			
Sedimentation rate (ESR)	1 time a week		4 treatments
Routine, Once, Starting S For 1 Occurrences			
□ CPK (creatine kinase)	1 time a week		4 treatments
Routine, Once, Starting S For 1 Occurrences			
	1 time a week		4 treatments

Routine, Once, Starting S For 1 Occurrences, The lipid panel consists of the following tests: Total Cholesterol, Triglycerides, Direct HDL, and Calculated LDL.

□ ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)	1 time a week	4 treatments
Routine, Once, Starting S For 1 Occurrences		
Urinalysis	1 time a	4 treatments
	week	

Routine, Once, Starting S For 1 Occurrences, *Except NWH* Urinalysis sediments are performed on all urines that have positive findings (blood, WBC, or protein) on the chemical urinalysis. Urine sediment does not need to be ordered separately.

Catheter management

	Interval	Defer Until	Duration
Line Access	PRN		Until discont'd
Routine, Once, Starting S For 1 Occurrences, As needed. Starting when released	I. Until Specified.		
Insert peripheral IV, or access peripheral, or central venous access device, to pro	vide treatment.		
alteplase (CATHFLO) 1 mg/mL injection 2 mg	PRN		Until discont'd
 2 mg, Intracatheter, As needed, line care, For central venous access device requirepeat once per lumen, Starting S	ring clearance. Adm	inister per institution	al guidelines. May
lidocaine-prilocaine (EMLA) cream	PRN		Until discont'd
Topical, As needed, pre procedure/treatment, Apply prior to the PIV insertion or p	ort access, Starting	S	
heparin 100 units/mL flush 5 mL	PRN		Until discont'd
5 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Sta	arting S		
heparin 10 units/mL flush 3 mL	PRN		Until discont'd
3 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Sta	arting S		
heparin 10 units/mL flush 5 mL	PRN		Until discont'd
5 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Sta	arting S		
heparin 1000 units/mL flush 2 mL	PRN		Until discont'd
2 mL, Intracatheter, As needed, line care, APHERESIS LINE CARE ONLY per ins FROM EACH LUMEN PRIOR TO FLUSHING OR INFUSING THROUGH THE AR			ITHDRAWN
sodium chloride (NS) 0.9 % syringe flush 3 mL	PRN		Until discont'd
3 mL, Intravenous, As needed, line care, Line care per institutional guidelines, Sta	arting S		
sodium chloride (NS) 0.9 % syringe flush 10 mL	PRN		Until discont'd
10 mL, Intravenous, As needed, line care, Line care per institutional guidelines, S	tarting S		
sodium chloride (NS) 0.9 % syringe flush 20 mL	PRN		Until discont'd
20 mL, Intravenous, As needed, line care, Line care per institutional guidelines, S	tarting S		
sodium chloride 0.9% infusion	PRN		Until discont'd

X b	COOLEY DICKINSON HOSPITAL MASSACHUSETTS GENERAL HOSPITAL AFFILIATE			(Patient Stic	ker)
	PHYSICIAN ORDER SET :				
	RITUXIMAB RHEUMATOLOGY VASCULITIS				
	CDH 208-237 – Approved - Page 4 of 5				
Cathe	ter management (continued)				
		Inter	val	Defer Until	Duration
	20 mL/hr, Intravenous, Continuous PRN, other (free text field), Keep vein open to provid	de trea	atment, S	tarting S	
	D5W infusion	PRN			Until discont'd
	20 mL/hr, Intravenous, Continuous PRN, other (free text field), Keep vein open to provid	de trea	atment, S	tarting S	
Emer	gency Medications				
		Inter	val	Defer Until	Duration
		PRN		Delei Ontil	Until discont'd
	Routine, Until discontinued, Starting S, Treatment of SEVERE reaction (ANAPHYLAXIS distress, or decreased oxygen saturation. Stop the infusion and treat with epinephrine F administer oxygen as needed, monitor vital signs and proceed with administering adjunct indicated.	FÍRST.	Notify pr	rovider and emerge	ncy personnel,
	EPINEPHrine injection 0.3 mg	PRN			Until discont'd
	0.3 mg, Intramuscular, As needed, anaphylaxis, Administer FIRST for anaphylaxis. May For 2 doses. Pharmacy's Suggested Dose Instructions; Epinephrine 1:1000 is equ			-	
	sodium chloride 0.9% bolus 1,000 mL	PRN			Until discont'd
	1,000 mL, Intravenous, Once as needed, other (free text field), For hypotension, Startin	ng S, F	or 1 Dose	es	
	Oxygen Therapy - Non-Rebreather Routine	PRN			Until discont'd
	Select a Mode of Therapy: Non-Rebreather				
	Tryptase STAT, Once, Starting S For 1 Occurrences Collect for mild-moderate, or SEVERE reaction	PRN			Until discont'd

		Interval	Defer Until	Duration
	Provider and Nurse Communication	PRN		Until discont'o
	Routine, Until discontinued, Starting S For Until specified, Treatment for mile and emergency personnel, administer oxygen as needed, monitor vital signs indicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section	s and proceed with admin		
	albuterol (ACCUNEB) nebulizer solution 2.5 mg	PRN		Until discont'o
	2.5 mg, Nebulization, Once as needed, shortness of breath, wheezing, whe	ezing, shortness of breath	, Starting S, For 1 D	oses
	acetaminophen (TYLENOL) tablet 975 mg	PRN		Until discont'd
	975 mg, Oral, Once as needed, fever, Starting S, For 1 Doses			
]	diphenhydrAMINE (BENADRYL) injection 25 mg	PRN		Until discont'o
	25~mg, Intravenous, As needed, itching, itching, hives. Begin with 25 mg. If Starting S	patient has continued rea	ction, administer add	itional 25 mg,
	famotidine (PEPCID) injection 20 mg	PRN		Until discont'o
	20 mg, Intravenous, Once as needed, other (free text field), Adjunct treatme premed, Starting S, For 1 Doses	ent for mild-moderate, or S	EVERE reaction Hol	d if: given as
	cetirizine (ZyrTEC) tablet 10-20 mg	PRN		Until discont'o
	10-20 mg, Oral, Once as needed, allergies, Adjunct treatment for mild-mode HOLD IF giving fexofenadine.	erate, or SEVERE reaction	n, Starting S, For 1 D	oses
	fexofenadine (ALLEGRA) tablet 90-180 mg	PRN		Until discont'o
	90-180 mg, Oral, Once as needed, allergies, Adjunct treatment for mild-mod	derate, or SEVERE reaction	on, Starting S, For 1	Doses
	HOLD IF giving cetirizine.			
]	methylprednisolone sodium succinate (SOLU-Medrol) IV	40 mg PRN		Until discont'o
	40 mg, Intravenous, Once as needed, other (free text field), Adjunct treatme	ent for mild-moderate, or S	SEVERE reaction, Sta	arting S, For 1

\sim	COOLEY DICKINSON
	HOSPITAL
V	MASSACHUSETTS GENERAL HOSPITAL AFFILIATE

PHYSICIAN ORDER SET :

RITUXIMAB RHEUMATOLOGY VASCULITIS

Approved -

CDH 208-237 –

Page 5 of 5

Hypersensitivity (continued)

	Interval	Defer Until	Duration
ondansetron (ZOFRAN) injection 4 mg	PRN		Until discont'd
4 mg, Intravenous, As needed, nausea, vomiting, may repeat x 1 dose, Starting	S, For 2 Doses		
meperidine (DEMEROL) injection 25 mg	PRN		Until discont'd

25 mg, Intravenous, Once as needed, rigors, Starting S, For 1 Doses

version 8/29/2017